Olszewska Z
Przegl Dermatol. 1989 Sep-Dec;76(5-6):430-4.
A retrospective analysis of survival time was carried out in 29 progressive systemic sclerosis patients treated with immunosuppressive drugs and in 15 patients who underwent another mode of treatment. It was found that fatality in both groups studied was the same (case fatality rate approximately 35%), but the mean survival time of those who had died was much longer for 10 patients treated with immunosuppressive drugs than for the 5 patients who had not undergone this mode of treatment (p less than 0.05). The cumulative survival rate evaluated at 5 years from the beginning of treatment was also higher in patients treated with immunosuppressive drugs (79.3%) than in the other group under investigation (66.7%). However the difference between these results was not statistically significant.
对29例接受免疫抑制药物治疗的进行性系统性硬化症患者和15例接受其他治疗方式的患者的生存时间进行了回顾性分析。结果发现，所研究的两组患者的死亡率相同（病死率约为35%），但在死亡患者中，接受免疫抑制药物治疗的10例患者的平均生存时间比未接受该治疗方式的5例患者长得多（p<0.05）。从治疗开始起5年时评估的累积生存率，接受免疫抑制药物治疗的患者（79.3%）也高于另一受调查组（66.7%）。然而，这些结果之间的差异无统计学意义。
